Topoisomerase I Is Essential in Cryptococcus neoformans: Role in Pathobiology and as an Antifungal Target

Corresponding author: John R. Perfect, Department of Medicine, Division of Infectious Diseases and International Health, Duke University Medical Center, P.O. Box 3353, Durham, NC 27710., perfe001{at}mc.duke.edu (E-mail)

Communicating editor: A. P. MITCHELL

Topisomerase I is the target of several toxins and chemotherapy agents, and the enzyme is essential for viability in some organisms, including mice and drosophila. We have cloned the TOP1 gene encoding topoisomerase I from the opportunistic fungal pathogen Cryptococcus neoformans. The C. neoformans topoisomerase I contains a fungal insert also found in topoisomerase I from Candida albicans and Saccharomyces cerevisiae that is not present in the mammalian enzyme. We were unable to disrupt the topoisomerase I gene in this haploid organism by homologous recombination in over 8000 transformants analyzed. When a second functional copy of the TOP1 gene was introduced into the genome, the topoisomerase I gene could be readily disrupted by homologous recombination (at 7% efficiency). Thus, topoisomerase I is essential in C. neoformans. This new molecular strategy with C. neoformans may also be useful in identifying essential genes in other pathogenic fungi. To address the physiological and pathobiological functions of the enzyme, the TOP1 gene was fused to the GAL7 gene promoter. The resulting GAL7::TOP1 fusion gene was modestly regulated by carbon source in a serotype A strain of C. neoformans. Modest overexpression of topoisomerase I conferred sensitivity to heat shock, -rays, and camptothecin. In contrast, alterations in topoisomerase I levels had no effect on the toxicity of a novel class of antifungal agents, the dicationic aromatic compounds (DACs), indicating that topoisomerase I is not the target of DACs. In an animal model of cryptococcal meningitis, topoisomerase I regulation was not critically important to established infection, but may impact on the initial stress response to infection. In summary, our studies reveal that topoisomerase I is essential in the human pathogen C. neoformans and represents a novel target for antifungal agents.

This article has been cited by other articles:

				P. T. Magee, C. Gale, J. Berman, and D. Davis Molecular Genetic and Genomic Approaches to the Study of Medically Important Fungi Infect. Immun., May 1, 2003; 71(5): 2299 - 2309. [Full Text] [PDF]

				T. H. Rude, D. L. Toffaletti, G. M. Cox, and J. R. Perfect Relationship of the Glyoxylate Pathway to the Pathogenesis of Cryptococcus neoformans Infect. Immun., October 1, 2002; 70(10): 5684 - 5694. [Abstract] [Full Text] [PDF]

				S. I. Khan, A. C. Nimrod, M. Mehrpooya, J. L. Nitiss, L. A. Walker, and A. M. Clark Antifungal Activity of Eupolauridine and Its Action on DNA Topoisomerases Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1785 - 1792. [Abstract] [Full Text] [PDF]

				J. A. Alspaugh, R. Pukkila-Worley, T. Harashima, L. M. Cavallo, D. Funnell, G. M. Cox, J. R. Perfect, J. W. Kronstad, and J. Heitman Adenylyl Cyclase Functions Downstream of the G{alpha} Protein Gpa1 and Controls Mating and Pathogenicity of Cryptococcus neoformans Eukaryot. Cell, February 1, 2002; 1(1): 75 - 84. [Abstract] [Full Text] [PDF]

				C. A. D'Souza, J. A. Alspaugh, C. Yue, T. Harashima, G. M. Cox, J. R. Perfect, and J. Heitman Cyclic AMP-Dependent Protein Kinase Controls Virulence of the Fungal Pathogen Cryptococcus neoformans Mol. Cell. Biol., May 1, 2001; 21(9): 3179 - 3191. [Abstract] [Full Text]

				C. Luberto, D. L. Toffaletti, E. A. Wills, S. C. Tucker, A. Casadevall, J. R. Perfect, Y. A. Hannun, and M. Del Poeta Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans Genes & Dev., January 15, 2001; 15(2): 201 - 212. [Abstract] [Full Text]

				P. Soteropoulos, T. Vaz, R. Santangelo, P. Paderu, D. Y. Huang, M. J. Tamás, and D. S. Perlin Molecular Characterization of the Plasma Membrane H+-ATPase, an Antifungal Target in Cryptococcus neoformans Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2349 - 2355. [Abstract] [Full Text]

				M. Del Poeta, S.-F. Chen, D. Von Hoff, C. C. Dykstra, M. C. Wani, G. Manikumar, J. Heitman, M. E. Wall, and J. R. Perfect Comparison of In Vitro Activities of Camptothecin and Nitidine Derivatives against Fungal and Cancer Cells Antimicrob. Agents Chemother., December 1, 1999; 43(12): 2862 - 2868. [Abstract] [Full Text]

				C. Yue, L. M. Cavallo, J. A. Alspaugh, P. Wang, G. M. Cox, J. R. Perfect, and J. Heitman The STE12{alpha} Homolog Is Required for Haploid Filamentation But Largely Dispensable for Mating and Virulence in Cryptococcus neoformans Genetics, December 1, 1999; 153(4): 1601 - 1615. [Abstract] [Full Text]

				M. E. Cardenas, M. C. Cruz, M. Del Poeta, N. Chung, J. R. Perfect, and J. Heitman Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System To Study Drug Action Clin. Microbiol. Rev., October 1, 1999; 12(4): 583 - 611. [Abstract] [Full Text] [PDF]

				M. D. Poeta, A. S. Bixel, F. Barchiesi, R. R. Tidwell, D. Boykin, G. Scalise, and J. R. Perfect In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp. J. Antimicrob. Chemother., August 1, 1999; 44(2): 223 - 228. [Abstract] [Full Text] [PDF]